Ingenol mebutate gel is effective treatment for actinic keratosis, study shows
Ingenol mebutate topical gel (0.015% for face and scalp and 0.05% for trunk and extremities) was effective for treating actinic keratoses, a common precursor to sun-related, squamous cell carcinoma, according to a new study.
Ingenol mebutate topical gel (0.015% for face and scalp and 0.05% for trunk and extremities) was effective for treating actinic keratoses, a common precursor to sun-related, squamous cell carcinoma, according to a new study.
The 4-multicenter, randomized, double-blind study, published in the March 15 issue of the New England Journal of Medicine, was led by Mark Lebwohl, MD. The study was funded by LEO Pharma.
In the study, patients with actinic keratoses on the face or scalp, or on the trunk or extremities, were randomly assigned to receive ingenol mebutate (Picato, LEO Pharma) or a placebo. Patients self-applied the medication or placebo to a 25-cm2 contiguous area once daily for 3 consecutive days for lesions on the face and scalp or for 2 consecutive days for lesions on the trunk or extremities.
Complete clearance (primary outcome) was assessed at 57 days, and local reactions were quantitatively measured.
The researchers found that the rate of complete clearance on the face and scalp was higher (42.2%) with ingenol mebutate than with placebo (3.7%). The rate of complete clearance on the trunk and extremities was 34.1% with ingenol mebutate versus 4.7% with the placebo. In addition, adverse events were generally mild to moderate in intensity.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
